JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval

On June 2, analyst Soumit Roy from JonesTrading maintained a Buy rating on Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) and retained the price target of $26.00.

The analyst supported the positive rating with Ojemda’s potential, which is a prescription medicine that treats certain brain tumor types. He reasoned that its ability to facilitate growth recovery in children under 12 years old highlights a key concern associated with its long-term adoption.

A closeup of pills in a pharmacy, representing the high quality medications of the company.

According to him, physicians at ASCO exhibited willingness to prescribe the drug as a first-line treatment because of its convenient once-weekly dosing in an outpatient setting, which distinguishes it from the other demanding requirements of chemotherapy.

Roy further reasoned that Ojemda has a favorable side effect profile when compared to other MEK inhibitors, as it causes less severe rashes that typically dissipate within a few months. He stated that it is a preferable option over chemotherapy for parents because of its reversible effect on growth suppression.

The drug’s use in treating pediatric glioma patients is also promising because of a lack of severe adverse events like intratumoral hemolysis and the continued durability of response post-discontinuation.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) develops and commercializes targeted therapies for genetically defined cancers in patients of all ages. Its products include DAY101 and pimsertib.

While we acknowledge the potential of DAWN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DAWN and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Debt Free IT Penny Stocks To Buy and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.